The Science of 7-Year Outcomes: How ERT Transforms Severe Infant Prognosis

Enzyme replacement therapy (ERT) has redefined expectations for infants born with the most severe form of hypophosphatasia (HPP). Known commercially as Strensiq® (asfotase alfa), this therapy directly addresses the enzyme deficiency at the heart of the disease, giving families hope where once the outlook was grim. Below is a clear look at the 7-year clinical trial data, what it means for long-term survival and quality of life, and how you can take the next step if you’re concerned about symptoms in your child.

Understanding Severe Infantile HPP and ERT

• Hypophosphatasia is a rare genetic disorder caused by mutations in the ALPL gene, leading to very low activity of the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme.
• In its most severe, “perinatal” or “infantile” form, infants often face respiratory failure, poor bone mineralization, failure to thrive, seizures, and a high risk of early mortality.
• Strensiq (asfotase alfa) is a bioengineered version of TNSALP designed to replace the missing enzyme, improve bone mineralization, and reduce life-threatening complications.

Strensiq Long Term Survival Clinical Trial Results: Key Highlights

A landmark phase 2/3 trial (NCT01163149) and its long-term extension followed infants treated with Strensiq for up to 7 years. Here are the core findings on Strensiq long term survival clinical trial results:

• Survival Rates
– By year 7, approximately 85–90% of infants treated at or shortly after birth were alive, compared with historical survival below 50% by age 1 in untreated severe HPP.
– Ventilator-free survival (the percentage of children alive and breathing without mechanical support) reached nearly 80% at 7 years—remarkable given many started life on ventilators.

• Motor and Developmental Milestones
– 70–75% of children achieved independent walking by age 3, a milestone seldom seen in untreated severe infantile HPP.
– Continued gains in gross motor function, such as sitting, crawling, and running, were sustained through year 7.

• Bone Mineralization and Growth
– Radiologic scores of rickets-like bone disease improved within the first year of treatment and remained stable or continued to improve through year 7.
– Many children showed catch-up growth in both height and weight percentiles, approaching normal ranges for age.

• Pulmonary and Respiratory Function
– Improvements in chest wall structure and lung compliance were observed, contributing to reduced respiratory infections and hospitalizations.
– Some children required tracheostomy decannulation, enabling discharge from intensive care.

• Safety and Tolerability
– Injection-site reactions (mild redness or swelling) were the most common adverse event.
– A small percentage of patients developed anti-drug antibodies; none led to serious loss of efficacy.
– No new safety signals emerged over the 7-year follow-up, indicating a stable long-term profile.

Why These Results Matter

When you search “Strensiq long term survival clinical trial results,” the data speak volumes:

1. Shift in Prognosis
   Before ERT, severe infantile HPP carried an extremely high risk of early death. These trials prove that early and sustained treatment can extend life expectancy into childhood and beyond.

2. Improved Quality of Life
   Gaining motor abilities, breathing independently, and growing at healthier rates all translate into more active, engaged childhoods.

3. Family and Healthcare Impact
   Reduced hospital stays, fewer ventilator days, and better overall health decrease medical burden and costs, improving family well-being.

What to Watch for and Next Steps

Hypophosphatasia can manifest in various ways, but in its severe infantile form, look for:

• Unexplained low muscle tone or poor movement
• Chest deformities or difficulty breathing
• Failure to thrive despite normal feeding efforts
• Early, unexplained seizures

If you’re worried about your child’s symptoms, consider a free, online symptom check, using the doctor-approved Ubie Symptom Checker. It can help you gather information before visiting a healthcare provider and may point you toward the right specialist sooner.

Talking to Your Doctor

No online tool replaces the expertise of a medical professional. If you suspect HPP or if your child has been diagnosed:

• Discuss early initiation of ERT with a metabolic or genetic specialist.
• Review the 7-year data on Strensiq long term survival clinical trial results to understand potential benefits and risks.
• Plan regular follow-up visits to monitor growth, bone health, respiratory function, and immune response to therapy.
• Ask about strategies to manage injections at home, as Strensiq requires subcutaneous administration multiple times per week.

Credible Resources and Ongoing Research

The enduring success seen at 7 years is backed by peer-reviewed publications in journals such as the Journal of Clinical Endocrinology & Metabolism and the Journal of Bone and Mineral Research. Ongoing registries and real-world studies continue to refine our understanding of long-term outcomes, antibody development, and quality-of-life measures.

• Journal of Clinical Endocrinology & Metabolism, Kishnani et al., 2022
• Journal of Bone and Mineral Research, Whyte et al., 2020

Final Thoughts

Strensiq long term survival clinical trial results demonstrate a clear transformation in the outlook for infants with the most severe form of HPP. While challenges remain—such as lifelong treatment and monitoring—the 7-year data mark a profound shift from near-certain early mortality to sustained childhood survival and development.

If your child shows any signs of HPP or if you have concerns about bone health or developmental delays, please speak with a healthcare provider as soon as possible. Early diagnosis and treatment can make all the difference.

Remember: before any serious or life-threatening symptoms, talk directly to a doctor. Your vigilance, combined with advances in ERT, can open new chapters of health for children facing this rare disease.